Inotropes and inopressors are often first-line treatment in patients with cardiogenic shock. We summarize the pharmacology, indications, and contraindications of dobutamine, milrinone, dopamine, norepinephrine, epinephrine, and levosimendan. We also review the data on the use of these medications for acute decompensated heart failure and cardiogenic shock in this article.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/FJC.0000000000001078 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Review of Inotropes and Inopressors for Effective Utilization in Patients With Acute Decompensated Heart Failure.
J Cardiovasc Pharmacol
September 2021
Division of Cardiology, Department of Medicine, Loma Linda University Medical Center, Loma Linda CA; and.
Inotropes and inopressors are often first-line treatment in patients with cardiogenic shock. We summarize the pharmacology, indications, and contraindications of dobutamine, milrinone, dopamine, norepinephrine, epinephrine, and levosimendan. We also review the data on the use of these medications for acute decompensated heart failure and cardiogenic shock in this article.
View Article and Find Full Text PDFDobutamine: ten years later.
Pharmacotherapy
October 1989
Eli Lilly and Company, Indianapolis, Indiana.
Dobutamine is a commonly used positive inotrope for the short-term management of heart failure. It is commercially available as a 50:50 mixture of two isomers with unique effects on alpha- and beta adrenergic receptors. In dosages of 2-15 micrograms/kg/minute, dobutamine has been shown to increase cardiac output (mainly through stroke volume), reduce systemic vascular resistance, lower central venous and pulmonary artery wedge pressures, improve renal blood flow, and relieve signs and symptoms of congestive heart failure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!